Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNU-2 study.

ABSTRACT:

Background

We explored the influence of BRAF and PIK3CA mutational status on the efficacy of bevacizumab or cetuximab plus 5-fluorouracil/leucovorin and irinotecan (FOLFIRI) as first-line therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC).

Patients and methods

VISNÚ-2 was a multicentre, randomised, phase II study. Patients with RAS wild-type mCRC and <3 circulating tumour cells/7.5 ml blood were stratified by BRAF/PIK3CA status (wild-type versus mutated) and number of affected organs (1 versus >1), and allocated to bevacizumab (5 mg/kg every 2 weeks) or cetuximab (400 mg/m² then 250 mg/m² weekly) plus FOLFIRI [irinotecan 180 mg/m², leucovorin 400 mg/m², 5-fluorouracil 400 mg/m² (bolus) then 2400 m

SUBMITTER: Sastre J 

PROVIDER: S-EPMC7970062 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature